This episode provides a detailed breakdown of the three pillars of performance evaluation required under the EU's In Vitro Diagnostic Regulation (IVDR): scientific validity, analytical performance, and clinical performance. We focus specifically on the heightened requirements and common pitfalls for manufacturers of high-risk Class C and D devices, explaining why underestimating the clinical evidence burden is a primary cause of delays in obtaining CE marking.

- What are the three essential pillars of a successful IVDR performance evaluation?

- Why is a Scientific Validity Report the foundational first step for your technical documentation?

- What specific data is required to demonstrate analytical performance under the new regulation?

- How has the burden for clinical performance evidence changed for Class C and D IVDs?

- What are the most common reasons for CE marking delays related to performance studies?

- How can you develop a robust clinical performance study plan that satisfies Notified Body scrutiny?

- What is the critical difference between analytical performance and clinical performance in the eyes of regulators?

Pure Global helps IVD companies conquer the challenges of global regulations like the EU IVDR. Our experts develop efficient regulatory strategies and manage the creation of technical dossiers, including complex Performance Evaluation Reports. We leverage advanced AI tools to streamline literature reviews and manage clinical data, ensuring your submission is robust and complete. Whether you're a startup or a multinational, we provide the support needed to navigate pre-submission activities and get your innovative IVDs to the European market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.